Key result
High serum chemerin was associated with a higher rate of cardiovascular diseases compared to low chemerin in incident peritoneal dialysis patients.
Why the study?
No serum markers related to peritoneal membrane transport function had been reported in peritoneal dialysis patients, and the role of chemerin in transport function and cardiovascular diseases in incident patients remained unknown.
Is serum chemerin associated with peritoneal membrane transport function and cardiovascular diseases in incident peritoneal dialysis patients?
Cohort (n=151)
No
Is serum chemerin associated with peritoneal membrane transport function and cardiovascular diseases in incident peritoneal dialysis patients?
Serum chemerin is positively correlated with baseline peritoneal membrane transport function and may serve as a biomarker for cardiovascular disease risk in incident peritoneal dialysis patients.
Answers are grounded in this paper and cite their sources.
Serum chemerin may support early transport risk stratification in incident PD; hypothesis-generating and requires validation before practice change.
INTRODUCTION: Some biomarkers in drained dialyzate or peritoneal membrane have been found related to the dialyzate/plasma ratio of creatinine at 4 h (D/P Cr) in patients undergoing peritoneal dialysis (PD). But so far, there is no report on serum markers. Some biomarkers are associated with cardiovascular diseases (CVDs). Chemerin is a multifunctional chemoattractant adipokine which plays important roles in inflammation, adipogenesis, and metabolism. We intended to investigate the role of chemerin in the peritoneal membrane transport function and CVDs in incident PD patients. METHODS: This prospective cohort study was conducted in our PD center. The patients underwent initial standardized peritoneal equilibration test after PD for 4-6 weeks. Level of serum chemerin was determined via enzyme-linked immunosorbent assay. The patients' CVDs were recorded during the follow-up period. RESULTS: 151 eligible patients with a mean age of 46.59 ± 13.52 years were enrolled, and the median duration of PD was 25.0 months. The median concentration of serum chemerin was 29.09 ng/mL. Baseline D/P Cr was positively correlated with serum chemerin (r = 0.244, p = 0.003). The multivariate analyses revealed that serum chemerin (p = 0.002), age (p = 0.041), albumin (p = 0.000), and high-density lipoprotein (p = 0.022) were independent factors of D/P Cr. The serum chemerin level was significantly higher in diabetes mellitus (DM) patients than that of patients without DM (36.45 ng/mL vs. 27.37 ng/mL, p = 0.000), and there was a significant statistical difference in CVDs between the high chemerin group (≥29.09 ng/mL) and low chemerin group (<29.09 ng/mL) (42 vs. 21%, p = 0.009). CONCLUSIONS: Serum chemerin has a positive correlation with baseline D/P Cr in incident PD patients. It may be a biomarker that can predict the baseline transport function of the peritoneal membrane, and serum chemerin may be a risk factor of CVDs for incident PD patients. Multicenter studies with a larger sample size are warranted in the future.
No takes yet. Share an insight, caveat, or question.
Zang et al. (2023) conducted a cohort in Incident peritoneal dialysis (n=151). High serum chemerin (≥29.09 ng/mL) vs. Low serum chemerin (<29.09 ng/mL) was evaluated on Cardiovascular diseases (CVDs) (p=0.009). High serum chemerin was associated with a higher rate of cardiovascular diseases compared to low chemerin in incident peritoneal dialysis patients.
Synapse has enriched 10 related papers. Consider them for comparative context: